Drugs / Lactobacillus crispatus
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07308808 | Sep 2025 → Mar 2027 expected | spinal cord injury, urinary tract infection | Medstar Health Research Institute | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07539805 | Jun 2026 → Feb 2028 expected | major depressive disorder | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07266532 | Dec 2025 | — | Shenzhen People's Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus crispatus | “Once daily, 3mL of Lactobacillus crispatus solution was applied to the bilateral forearms at a diameter of 3cm 10cm from the carpal wrinkles” NCT07266532 ↗ |
| Route | Topical | “topical application of Lactobacillus crispatus” NCT07266532 ↗ |